The New B7s: Playing a Pivotal Role in Tumor Immunity
The DOI matches its Crossref record; 118 of the 118 references it cites were found in a registry or an index.
Abstract
B7-H1, B7-DC, B7-H2, B7-H3, and B7-H4, all new additions to the B7 family, here termed "the new B7s," are emerging as important tools in directing immune function; each with unique, yet often overlapping functions. Clearly, each B7 molecule has developed its own indispensable niche in the immune system. The expression of both stimulatory and inhibitory B7 molecules seems to play an essential role in regulating the immune response to transformed cells through a variety of mechanisms. As specific niches of B7 family members continue to be dissected, their diagnostic and therapeutic potential becomes ever more apparent. In this review, we will discuss the role of the new B7s in activation and inhibition of antitumor immune responses, their prospects in diagnostics, and also potential and developing immunotherapy protocols.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
3 retracted
Radhakrishnan, S., Nguyen, L. T., Ćirić, B., Ure, D., Zhou, B., Tamada, K., Dong, H., Tseng, S.-Y., Shin, T., Pardoll, D. M., et al. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.170.4.1830 · Cited by 73
Self-citationRetractedImmunotherapeutic Potential of B7-DC (PD-L2) Cross-Linking Antibody In Conferring Antitumor Immunity
Radhakrishnan, S., Nguyen, L. T., Ciric, B., Flies, D., Keulen, V. P. V., Tamada, K., Chen, L., Rodriguez, M., & Pease, L. R. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3025 · Cited by 59 · cited 4×
“Evidence of 3 B7-DC splice variants and the likelihood of reverse signaling through the intracellular domain make studies of this receptorligand pathway exceedingly complex.(20,21) Indeed, studies in autoimmune models show widely varying outcomes in B7-H1 versus B7-DC blockade, neither of which correlate well with PD-…”
BackgroundResultInfluentialSelf-citationRetractedRadhakrishnan, S., Celis, E., & Pease, L. R. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0501420102 · Cited by 41
RetractedTumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
Dong, H., Strome, S. E., Salomao, D. R., Tamura, H., Hirano, F., Flies, D. B., Roche, P. C., Lu, J., Zhu, G., Tamada, K., et al. (2002) · Nature Medicine · doi:10.1038/nm730 · Cited by 5,025
Self-citationRestoring function in exhausted CD8 T cells during chronic viral infection
Barber, D. L., Wherry, E. J., Masopust, D., Zhu, B., Allison, J. P., Sharpe, A. H., Freeman, G. J., & Ahmed, R. (2006) · Nature · doi:10.1038/nature04444 · Cited by 3,986
Iwai, Y., Ishida, M., Tanaka, Y., Okazaki, T., Honjo, T., & Minato, N. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.192461099 · Cited by 3,203
PD-L2 is a second ligand for PD-1 and inhibits T cell activation
Latchman, Y., Wood, C. R., Chernova, T., Chaudhary, D., Borde, M., Chernova, I., Iwai, Y., Long, A. J., Brown, J. A., Nunes, R., et al. (2001) · Nature Immunology · doi:10.1038/85330 · Cited by 2,955 · cited 3×
“B7-DC protein expression is predominantly restricted to DCs and macrophages, although mRNA can be found in a wide range of tissues.(15,16,92,93) B7-DC is not typically expressed in tumors, in contrast to B7-H1.”
BackgroundDong, H., Zhu, G., Tamada, K., & Chen, L. (1999) · Nature Medicine · doi:10.1038/70932 · Cited by 2,496 · cited 1×
“The regulation of B7-H1 (PD-L1, CD274) seems to be a pivotal molecule in shaping the immune response to tumors, and fittingly, B7-H1 was first identified as an EST clone of human ovarian carcinoma.(14) Shortly thereafter, B7-DC (PD-L2, CD273) was discovered to be preferentially expressed on DCs.”
BackgroundSelf-citationGreenwald, R. J., Freeman, G. J., & Sharpe, A. H. (2005) · Annual Review of Immunology · doi:10.1146/annurev.immunol.23.021704.115611 · Cited by 2,318 · cited 1×
“On the basis of current research, each molecule seems capable of a range of functional outcomes based on regulated expression on tumors, T cells, dendritic cells (DCs), macrophages, B cells, or parenchymal cells such as epithelial cells.(8) Understanding the multivariate functions of the cohort of B7 molecules in vivo…”
BackgroundBretscher, P., & Cohn, M. (1970) · Science · doi:10.1126/science.169.3950.1042 · Cited by 1,692
Phan, G. Q., Yang, J. C., Sherry, R. M., Hwu, P., Topalian, S. L., Schwartzentruber, D. J., Restifo, N. P., Haworth, L. R., Seipp, C. A., Freezer, L. J., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1533209100 · Cited by 1,575 · cited 1×
“To demonstrate the influence of inhibitory cell surface molecules to abate and/or evade antitumor immune responses, blockade of the inhibitory molecule CTLA-4 has been show to be a very powerful mechanism for activation of T-cell responses in vivo.(109,110) Along these lines, it has become apparent that regulation of…”
BackgroundCo-inhibitory molecules of the B7–CD28 family in the control of T-cell immunity
Chen, L. (2004) · Nature Reviews Immunology · doi:10.1038/nri1349 · Cited by 1,257 · cited 1×
“Both molecules bind the inhibitory receptor PD-1 (CD279), while ample evidence exists that both molecules also bind a second, as yet unidentified receptor(s).(19) Evidence of 3 B7-DC splice variants and the likelihood of reverse signaling through the intracellular domain make studies of this receptorligand pathway exc…”
BackgroundSelf-citationTissue expression of PD-L1 mediates peripheral T cell tolerance
Keir, M. E., Liang, S. C., Guleria, I., Latchman, Y. E., Qipo, A., Albacker, L. A., Koulmanda, M., Freeman, G. J., Sayegh, M. H., & Sharpe, A. H. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20051776 · Cited by 1,211
Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity
Hirano, F., Kaneko, K., Tamura, H., Dong, H., Wang, S., Ichikawa, M., Rietz, C., Flies, D. B., Lau, J. S., Zhu, G., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.1089.65.3 · Cited by 1,018 · cited 2×
“76,80,85,113,114 Furthermore, combination therapy of B7-H1 blocking mAb along with a costimulatory CD137 mAb enhanced tumor regression.(72) In a recent model by Geng et al,(115) B7-H1 blockade with soluble PD-1 in combination with an HSP70 vaccine increased TH1 cytokines and antitumor immunity in a murine lung metasta…”
BackgroundSelf-citationB7-H3: A costimulatory molecule for T cell activation and IFN-γ production
Chapoval, A. I., Ni, J., Lau, J. S., Wilcox, R. A., Flies, D. B., Liu, D., Dong, H., Sica, G. L., Zhu, G., Tamada, K., et al. (2001) · Nature Immunology · doi:10.1038/85339 · Cited by 1,015
Self-citationHodi, F. S., Mihm, M. C., Soiffer, R. J., Haluska, F. G., Butler, M., Seiden, M. V., Davis, T., Henry-Spires, R., MacRae, S., Willman, A., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0830997100 · Cited by 1,006 · cited 1×
“To demonstrate the influence of inhibitory cell surface molecules to abate and/or evade antitumor immune responses, blockade of the inhibitory molecule CTLA-4 has been show to be a very powerful mechanism for activation of T-cell responses in vivo.(109,110) Along these lines, it has become apparent that regulation of…”
BackgroundExpression of Programmed Death 1 Ligands by Murine T Cells and APC
Yamazaki, T., Akiba, H., Iwai, H., Matsuda, H., Aoki, M., Tanno, Y., Shin, T., Tsuchiya, H., Pardoll, D. M., Okumura, K., et al. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.169.10.5538 · Cited by 951 · cited 1×
“B7-DC protein expression is predominantly restricted to DCs and macrophages, although mRNA can be found in a wide range of tissues.(15,16,92,93) B7-DC is not typically expressed in tumors, in contrast to B7-H1.”
Carreno, B. M., & Collins, M. (2002) · Annual Review of Immunology · doi:10.1146/annurev.immunol.20.091101.091806 · Cited by 896
B7-Dc, a New Dendritic Cell Molecule with Potent Costimulatory Properties for T Cells
Tseng, S.-Y., Otsuji, M., Gorski, K., Huang, X., Slansky, J. E., Pai, S. I., Shalabi, A., Shin, T., Pardoll, D. M., & Tsuchiya, H. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.193.7.839 · Cited by 872 · cited 3×
“B7-DC protein expression is predominantly restricted to DCs and macrophages, although mRNA can be found in a wide range of tissues.(15,16,92,93) B7-DC is not typically expressed in tumors, in contrast to B7-H1.”
BackgroundThompson, R. H., Kuntz, S. M., Leibovich, B. C., Dong, H., Lohse, C. M., Webster, W. S., Sengupta, S., Frank, I., Parker, A. S., Zincke, H., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4303 · Cited by 869
Adoptive immunotherapy for cancer: building on success
Gattinoni, L., Powell, D. J., Rosenberg, S. A., & Restifo, N. P. (2006) · Nature Reviews Immunology · doi:10.1038/nri1842 · Cited by 845 · cited 3×
“Lately, a variety of cancer vaccines, adoptive cell transfer therapies (ACT) combined with preconditioning regimens, and molecular immunotherapies have achieved variable success in the clinic.(13,104,105) Please refer to the review by Gattinoni et al(13) for an update on adoptive immunotherapy for cancer.”
BackgroundThe Programmed Death-1 (PD-1) Pathway Regulates Autoimmune Diabetes in Nonobese Diabetic (NOD) Mice
Ansari, M. J. I., Salama, A. D., Chitnis, T., Smith, R. N., Yagita, H., Akiba, H., Yamazaki, T., Azuma, M., Iwai, H., Khoury, S. J., et al. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20022125 · Cited by 814
Ohigashi, Y., Sho, M., Yamada, Y., Tsurui, Y., Hamada, K., Ikeda, N., Mizuno, T., Yoriki, R., Kashizuka, H., Yane, K., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1469 · Cited by 796 · cited 2×
“However, B7-DC expression has been observed in immunohistochemical studies of nonsmall cell lung cancer and esophageal cancer, often coexpressed with B7H1.(59,62) As B7-DC seems to function largely as a costimulatory molecule, inducing TH1 cytokines, CTL, and antitumor responses, it may be surmised that the presence o…”
BackgroundT-cell co-stimulation through B7RP-1 and ICOS
Yoshinaga, S. K., Whoriskey, J. S., Khare, S. D., Sarmiento, U., Guo, J., Horan, T., Shih, G., Zhang, M., Coccia, M. A., Kohno, T., et al. (1999) · Nature · doi:10.1038/45582 · Cited by 777
Thompson, R. H., Gillett, M. D., Cheville, J. C., Lohse, C. M., Dong, H., Webster, W. S., Krejci, K. G., Lobo, J. R., Sengupta, S., Chen, L., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0406351101 · Cited by 776
Self-citationBlank, C., Brown, I., Peterson, A. C., Spiotto, M., Iwai, Y., Honjo, T., & Gajewski, T. F. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3259 · Cited by 772
B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma
Kryczek, I., Zou, L., Rodriguez, P., Zhu, G., Wei, S., Mottram, P., Brumlik, M., Cheng, P., Curiel, T., Myers, L., et al. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20050930 · Cited by 748
Self-citationT-cell antigen CD28 mediates adhesion with B cells by interacting with activation antigen B7/BB-1.
Linsley, P. S., Clark, E. A., & Ledbetter, J. A. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.13.5031 · Cited by 747
B7-H4, a Molecule of the B7 Family, Negatively Regulates T Cell Immunity
Sica, G. L., Choi, I.-H., Zhu, G., Tamada, K., Wang, S.-D., Tamura, H., Chapoval, A. I., Flies, D. B., Bajorath, J., & Chen, L. (2003) · Immunity · doi:10.1016/s1074-7613(03)00152-3 · Cited by 713 · cited 3×
“B7-H4 has been found to strongly inhibit immune responses through several mechanisms, therefore contributing to tumor escape from immune surveillance in a powerful way.(48,51) B7-H4 is expressed widely in human tumors, as has been confirmed by immunohistochemical analysis and quantitative polymerase chain reaction.”
BackgroundSelf-citationKonishi, J., Yamazaki, K., Azuma, M., Kinoshita, I., Dosaka-Akita, H., & Nishimura, M. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0428 · Cited by 678 · cited 2×
“However, B7-DC expression has been observed in immunohistochemical studies of nonsmall cell lung cancer and esophageal cancer, often coexpressed with B7H1.(59,62) As B7-DC seems to function largely as a costimulatory molecule, inducing TH1 cytokines, CTL, and antitumor responses, it may be surmised that the presence o…”
BackgroundBlank, C., Gajewski, T. F., & Mackensen, A. (2005) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-004-0593-x · Cited by 637 · cited 1×
“As numerous models, both in vitro and in vivo, have clearly shown that blockade of B7-H1 on tumors with antagonistic antibodies abrogates tumor resistance to CTL attack and induction of immunity, whereas both PD-1 deficient mice and PD-1 blockade with mAb also enhance tumor immunity and autoimmune mechanisms.(18,73) I…”
BackgroundGhebeh, H., Mohammed, S., Al-Omair, A., Qattant, A., Lehe, C., Al-Qudaihi, G., Elkum, N., Alshabanah, M., Bin Amer, S., Tulbah, A., et al. (2006) · Neoplasia · doi:10.1593/neo.05733 · Cited by 612
The B7 family member B7-H3 preferentially down-regulates T helper type 1–mediated immune responses
Suh, W.-K., Gajewska, B. U., Okada, H., Gronski, M. A., Bertram, E. M., Dawicki, W., Duncan, G. S., Bukczynski, J., Plyte, S., Elia, A., et al. (2003) · Nature Immunology · doi:10.1038/ni967 · Cited by 576
B7-H1 blockade augments adoptive T-cell immunotherapy for squamous cell carcinoma.
Strome, S. E., Dong, H., Tamura, H., Voss, S. G., Flies, D. B., Tamada, K., Salomão, D. R., Cheville, J. C., Hirano, F., Lin, W. Y., et al. (2003) · PubMed · Cited by 546
Self-citationToll-Like Receptors on Tumor Cells Facilitate Evasion of Immune Surveillance
Huang, B., Zhao, J., Li, H., He, K.-L., Chen, Y., Mayer, L., Unkeless, J. C., & Xiong, H. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0784 · Cited by 542
Iwai, Y. (2004) · International Immunology · doi:10.1093/intimm/dxh194 · Cited by 527 · cited 1×
“18,81 B7-H1 expressed on cells lining blood vessels or tissue hematopoietic cells such as macrophages may aid in inhibiting CTL activity to malignant cancers, as it was shown in B16 and CT26 metastatic tumor models that the hematogenous spread of cancer was inhibited in PD-1 deficient mice resulting in CTL proliferati…”
BackgroundSalama, A. D., Chitnis, T., Imitola, J., Ansari, M. J. I., Akiba, H., Tushima, F., Azuma, M., Yagita, H., Sayegh, M. H., & Khoury, S. J. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20022119 · Cited by 506
Wu, C., Zhu, Y., Jiang, J., Zhao, J., Zhang, X.-G., & Xu, N. (2006) · Acta Histochemica · doi:10.1016/j.acthis.2006.01.003 · Cited by 495
B7h, a Novel Costimulatory Homolog of B7.1 and B7.2, Is Induced by TNFα
Swallow, M. M., Wallin, J. J., & Sha, W. C. (1999) · Immunity · doi:10.1016/s1074-7613(00)80117-x · Cited by 453
Lee, S.-J., Jang, B.-C., Lee, S.-W., Yang, Y.-I., Suh, S.-I., Park, Y.-M., Oh, S., Shin, J.-G., Yao, S., Chen, L., et al. (2006) · FEBS Letters · doi:10.1016/j.febslet.2005.12.093 · Cited by 446 · cited 2×
“Furthermore, B7-H1 can be up-regulated by interferon-g (IFN-g) in many cells types,54 including both murine and human tumor cells lines, because of several IFN responsive elements in the promoter region, particularly IRF-1.”
BackgroundSelf-citationB7S1, a Novel B7 Family Member that Negatively Regulates T Cell Activation
Prasad, D. V. R., Richards, S., Mai, X. M., & Dong, C. (2003) · Immunity · doi:10.1016/s1074-7613(03)00147-x · Cited by 431 · cited 1×
“B7-H4 remains an orphan ligand, although evidence suggests a receptor can be induced on T cells.(48,49) B7-H4 has been found to strongly inhibit immune responses through several mechanisms, therefore contributing to tumor escape from immune surveillance in a powerful way.”
BackgroundYang, Z.-Z., Novak, A. J., Stenson, M. J., Witzig, T. E., & Ansell, S. M. (2006) · Blood · doi:10.1182/blood-2005-08-3376 · Cited by 420
Coyle, A. J., & Gutierrez-Ramos, J.-C. (2001) · Nature Immunology · doi:10.1038/85251 · Cited by 413 · cited 1×
“1–4 Flanked within this 40 year period, immunology research has progressed rapidly, the 2-signal model is accepted theory, albeit with a host of modifications along the way, including the identification of a crowd of ‘‘second-signal’’ molecules, many having inhibitory functions.(5) However, aside for the B7-1/2:CD28/…”
BackgroundB7x: A widely expressed B7 family member that inhibits T cell activation
Zang, X., Loke, P., Kim, J., Murphy, K., Waitz, R., & Allison, J. P. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1434299100 · Cited by 405
Murine B7-H3 is a negative regulator of T cells
Prasad, D. V. R., Nguyen, T., Li, Z., Yang, Y., Duong, J., Wang, Y., & Dong, C. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.4.2500 · Cited by 368
Wintterle, Schreiner, Mitsdoerffer, Schneider, Chen, Meyermann, Weller, M., & Wiendl (2003) · 中国神经肿瘤杂志 · Cited by 366
Spinning molecular immunology into successful immunotherapy
Pardoll, D. M. (2002) · Nature Reviews Immunology · doi:10.1038/nri774 · Cited by 360 · cited 1×
“Certainly, the new B7s will play a vital and exciting role in building on the early successes of adoptive and molecular immunotherapy.(12,13)”
BackgroundB7-H3 and B7-H4 expression in non-small-cell lung cancer
Sun, Y., Wang, Y., Zhao, J., Gu, M., Giscombe, R., Lefvert, A. K., & Wang, X. (2006) · Lung Cancer · doi:10.1016/j.lungcan.2006.05.012 · Cited by 316 · cited 1×
“B7-H3 protein expression has been immunohistologically detected in gastric, nonsmall cell lung, and neuroblastoma (4Ig isoform) cancers, and also on many human tumor cell lines.(39,41,46,65) Human neuroblastoma tumors and cells lines expressing the 4Ig isoform of B7-H3 may inhibit an NK-mediated immune response,(46) w…”
BackgroundFreedman, A. S., Freeman, G. J., Rhynhart, K., & Nadler, L. M. (1991) · Cellular Immunology · doi:10.1016/0008-8749(91)90091-o · Cited by 312
Krambeck, A. E., Thompson, R. H., Dong, H., Lohse, C. M., Park, E. S., Kuntz, S. M., Leibovich, B. C., Blute, M. L., Cheville, J. C., & Kwon, E. D. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0600937103 · Cited by 305
Blockade of PD‐L1 (B7‐H1) augments human tumor‐specific T cell responses in vitro
Blank, C., Kuball, J., Voelkl, S., Wiendl, H., Becker, B., Walter, B., Majdic, O., Gajewski, T. F., Theobald, M., Andreesen, R., et al. (2006) · International Journal of Cancer · doi:10.1002/ijc.21775 · Cited by 297
Characterization of Mouse and Human B7-H3 Genes
Sun, M., Richards, S., Prasad, D. V. R., Mai, X. M., Rudensky, A., & Dong, C. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.168.12.6294 · Cited by 295 · cited 1×
“The cloning of the original B7-H3 with single IgV-like and IgC-like domains was followed recently by the identification of a human isoform with dual IgV-like and IgC-like domains.(40) B7-H3 has been detected on several human tumor cells lines, whereas mRNA is broadly expressed in normal tissues and primarily on activa…”
BackgroundCastriconi, R., Dondero, A., Augugliaro, R., Cantoni, C., Carnemolla, B., Sementa, A. R., Negri, F., Conte, R., Corrias, M. V., Moretta, L., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0405025101 · Cited by 294 · cited 2×
“Moreover, this molecule may potentially play a diverse role in the regulation of growth and differentiation of nonhematopoietic tissues.(41,45,46) Unfortunately, all studies to date have been hindered by the as-yet-unidentified receptor(s), expressed primarily on activated T and NK cells.”
BackgroundYokochi, T., Holly, R. D., & Clark, E. A. (1982) · The Journal of Immunology · doi:10.4049/jimmunol.128.2.823 · Cited by 292
Wang, S., Bajorath, J., Flies, D. B., Dong, H., Honjo, T., & Chen, L. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20021752 · Cited by 291
Self-citationIshida, M., Iwai, Y., Tanaka, Y., Okazaki, T., Freeman, G. J., Minato, N., & Honjo, T. (2002) · Immunology Letters · doi:10.1016/s0165-2478(02)00142-6 · Cited by 280 · cited 1×
“B7-DC protein expression is predominantly restricted to DCs and macrophages, although mRNA can be found in a wide range of tissues.(15,16,92,93) B7-DC is not typically expressed in tumors, in contrast to B7-H1.”
Kryczek, I., Wei, S., Zou, L., Zhu, G., Mottram, P., Xu, H., Chen, L., & Zou, W. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.1.40 · Cited by 277
Self-citationB7-H1 pathway and its role in the evasion of tumor immunity
Dong, H., & Chen, L. (2003) · Journal of Molecular Medicine · doi:10.1007/s00109-003-0430-2 · Cited by 276 · cited 4×
“14,67 Therefore, the early finding that B7H1 induced IFN-g, interleukin-10 (IL-10), and granulocyte macrophage colony-stimulating factor production and proliferation of T cells in vitro are indeed genuine, however, the late downstream effects of signaling initiated through the B7-H1:PD-1:unidentified receptor network…”
BackgroundInfluentialSelf-citationCostimulation of T cells by B7-H2, a B7-like molecule that binds ICOS
Wang, S., Zhu, G., Chapoval, A. I., Dong, H., Tamada, K., Ni, J., & Chen, L. (2000) · Blood · doi:10.1182/blood.v96.8.2808 · Cited by 257
Self-citationChoi, I.-H., Zhu, G., Sica, G. L., Strome, S. E., Cheville, J. C., Lau, J. S., Zhu, Y., Flies, D. B., Tamada, K., & Chen, L. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.171.9.4650 · Cited by 246 · cited 3×
“Protein expression of B7-H4 has been difficult to detect, however, mRNA is expressed broadly in many tissues and organs.(47,48) B7-H4 remains an orphan ligand, although evidence suggests a receptor can be induced on T cells.”
BackgroundSelf-citationB7-H4 Is Highly Expressed in Ductal and Lobular Breast Cancer
Tringler, B., Zhuo, S., Pilkington, G., Torkko, K. C., Singh, M., Lucia, M. S., Heinz, D. E., Papkoff, J., & Shroyer, K. R. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1658 · Cited by 219 · cited 3×
“B7-H1 has been shown to be a marker inversely correlated with a positive outcome in studies of nonsmall cell lung cancer, esophageal cancer, gastric carcinoma, and renal cell carcinoma, whereas B7-H4 is expressed in nearly 100% of breast adenocarcinomas, and almost 90% of the time in uterine and ovarian cancer.(52) In…”
BackgroundB7-H1 costimulation preferentially enhances CD28-independent T-helper cell function
Tamura, H., Dong, H., Zhu, G., Sica, G. L., Flies, D. B., Tamada, K., & Chen, L. (2001) · Blood · doi:10.1182/blood.v97.6.1809 · Cited by 218 · cited 1×
“14,67 Therefore, the early finding that B7H1 induced IFN-g, interleukin-10 (IL-10), and granulocyte macrophage colony-stimulating factor production and proliferation of T cells in vitro are indeed genuine, however, the late downstream effects of signaling initiated through the B7-H1:PD-1:unidentified receptor network…”
BackgroundSelf-citationSalceda, S., Tang, T., Kmet, M., Munteanu, A., Ghosh, M., Macina, R., Liu, W., Pilkington, G., & Papkoff, J. (2005) · Experimental Cell Research · doi:10.1016/j.yexcr.2005.01.018 · Cited by 217 · cited 5×
“Although many cancers express these molecules on their surface, many established cancer cell lines do not constitutively express these molecules.(47,51,54) Such expression data indicate that these molecules are likely differentially regulated at the posttranscriptional level, as mRNA is fairly ubiquitously expressed.”
BackgroundInfluentialMak, T. W., Shahinian, A., Yoshinaga, S. K., Wakeham, A., Boucher, L.-M., Pintilie, M., Duncan, G., Gajewska, B. U., Gronski, M., Eriksson, U., et al. (2003) · Nature Immunology · doi:10.1038/ni947 · Cited by 209
Interferon γ: a crucial role in the function of induced regulatory T cells in vivo
Wood, K. J., & Sawitzki, B. (2006) · Trends in Immunology · doi:10.1016/j.it.2006.02.008 · Cited by 207
Molecular cloning and characterization of murine ICOS and identification of B7h as ICOS ligand
Mages, H. W., Hutloff, A., Heuck, C. J., Büchner, K., Himmelbauer, H., Oliveri, F., & Kroczek, R. A. (2000) · European Journal of Immunology · doi:10.1002/(sici)1521-4141(200004)30:4<1040::aid-immu1040>3.0.co;2-6 · Cited by 195
Luo, L., Chapoval, A. I., Flies, D. B., Zhu, G., Hirano, F., Wang, S., Lau, J. S., Dong, H., Tamada, K., Flies, A. S., et al. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.9.5445 · Cited by 181
Self-citationBlockade of B7-H1 Suppresses the Development of Chronic Intestinal Inflammation
Kanai, T., Totsuka, T., Uraushihara, K., Makita, S., Nakamura, T., Koganei, K., Fukushima, T., Akiba, H., Yagita, H., Okumura, K., et al. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.171.8.4156 · Cited by 170 · cited 1×
“In addition, blockade of B7-H1 by mAb inhibited T-cell response and ameliorated colitis in a mouse model.(87) A possible interpretation for these seemingly contradictory findings is the existence of an alternative receptor which is stimulatory for T-cell responses.”
BackgroundSelf-citationLocal expression of B7-H1 promotes organ-specific autoimmunity and transplant rejection
Subudhi, S. K., Zhou, P., Yerian, L. M., Chin, R. K., Lo, J. C., Anders, R. A., Sun, Y., Chen, L., Wang, Y., Alegre, M.-L., et al. (2004) · Journal of Clinical Investigation · doi:10.1172/jci19210 · Cited by 161 · cited 2×
“Transgenic expression of B7-H1 in pancreatic islet under the control of the insulin promoter promoted islet rejection.(86) In addition, blockade of B7-H1 by mAb inhibited T-cell response and ameliorated colitis in a mouse model.”
BackgroundSelf-citationEnhancement of CD8+ T Cell Responses by ICOS/B7h Costimulation
Wallin, J. J., Liang, L., Bakardjiev, A., & Sha, W. C. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.167.1.132 · Cited by 155 · cited 2×
“Although B7-H2 has been primarily shown to costimulate an antitumor immune response when expressed on solid tumors, evidence indicates that expression on hematologic malignancies promotes their expansion and is associated with shorter survival time.(34,36,37) B7-H2 protein and mRNA expression on solid tumors such as c…”
BackgroundIn vivo costimulatory role of B7-DC in tuning T helper cell 1 and cytotoxic T lymphocyte responses
Shin, T., Yoshimura, K., Shin, T., Crafton, E. B., Tsuchiya, H., Housseau, F., Koseki, H., Schulick, R. D., Chen, L., & Pardoll, D. M. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20050072 · Cited by 154 · cited 5×
“Supporting a costimulatory function for B7-DC, convincing evidence demonstrates that B7-DC knockout mice bearing CT26 hepatic metastases succumb more quickly to rapidly growing tumor than do wt mice, with a concomitant decrease in AH-1 specific CTL in the livers of B7-DC knockout mice.(94) These data are clearly in ag…”
BackgroundResultInfluentialSelf-citationB7DC/PDL2 Promotes Tumor Immunity by a PD-1–independent Mechanism
Liu, X., Gao, J. X., Wen, J., Yin, L., Li, O., Zuo, T., Gajewski, T. F., Fu, Y.-X., Zheng, P., & Liu, Y. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20022089 · Cited by 147 · cited 3×
“59,62 As B7-DC seems to function largely as a costimulatory molecule, inducing TH1 cytokines, CTL, and antitumor responses, it may be surmised that the presence of B7-DC in tumor samples copositive for B7H1 is being overshadowed by the powerful inhibitory effect of B7-H1.”
BackgroundKaufman, H. L. (2005) · Journal of Clinical Investigation · doi:10.1172/jci24624 · Cited by 145 · cited 1×
“4).(107,108) Even though potent antiimmune responses can now be generated both in vitro (for ACT) and in vivo, a bevy of inhibitory mechanisms naturally bring immune responses under control before a cancer can be completely eradicated.”
BackgroundB7-DC Regulates Asthmatic Response by an IFN-γ-Dependent Mechanism
Matsumoto, K., Inoue, H., Nakano, T., Tsuda, M., Yoshiura, Y., Fukuyama, S., Tsushima, F., Hoshino, T., Aizawa, H., Akiba, H., et al. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.4.2530 · Cited by 143
Wu, C.-P., Jiang, J.-T., Tan, M., Zhu, Y.-B., Ji, M., Xu, K.-F., Zhao, J.-M., Zhang, G.-B., & Zhang, X.-G. (2006) · World Journal of Gastroenterology · doi:10.3748/wjg.v12.i3.457 · Cited by 141 · cited 2×
“1%), thus suggesting B7-H3 plays a stimulatory role.(100) What is more, evidence from murine tumor models and a human melanoma cell line expressing B7-H3 evince antitumor responses.”
BackgroundIFN-gamma regulates the expression of B7-H1 in dermal fibroblast cells
Lee, S., SEO, S., Kim, B. C., Kim, C. D., Lee, J. H., Kang, J., Maeng, P. J., & Lim, J. (2005) · Journal of Dermatological Science · doi:10.1016/j.jdermsci.2005.06.008 · Cited by 138
Mouse B7-H3 induces antitumor immunity
Sun, X., Vale, M., Leung, E. Y., Kanwar, J. R., Gupta, R., & Krissansen, G. W. (2003) · Gene Therapy · doi:10.1038/sj.gt.3302070 · Cited by 137
Yamazaki, T., Akiba, H., Koyanagi, A., Azuma, M., Yagita, H., & Okumura, K. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.175.3.1586 · Cited by 136
Tamura, H., Dan, K., Tamada, K., Nakamura, K., Shioi, Y., Hyodo, H., Wang, S.-D., Dong, H., Chen, L., & Ogata, K. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2672 · Cited by 133
Self-citationWang, S., & Chen, L. (2004) · Microbes and Infection · doi:10.1016/j.micinf.2004.03.007 · Cited by 133 · cited 1×
“However, aside for the B7-1/2:CD28/ CTLA-4 network, the B7 family had largely languished in terms of newly identified members, primarily because of the low level of amino acid homology between members.(6) Only within the past decade have new B7 members burst into immunology research, and flourished as their complex ro…”
BackgroundSelf-citationSaudemont, A., Jouy, N., Hetuin, D., & Quesnel, B. (2005) · Blood · doi:10.1182/blood-2004-09-3458 · Cited by 132 · cited 1×
“3).(85) Transgenic expression of B7-H1 in pancreatic islet under the control of the insulin promoter promoted islet rejection.”
BackgroundTsushima, F., Iwai, H., Otsuki, N., Abe, M., Hirose, S., Yamazaki, T., Akiba, H., Yagita, H., Takahashi, Y., Omura, K., et al. (2003) · European Journal of Immunology · doi:10.1002/eji.200324084 · Cited by 125
Zhu, B., Guleria, I., Khosroshahi, A., Chitnis, T., Imitola, J., Azuma, M., Yagita∥, H., Sayegh, M. H., & Khoury, S. J. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.6.3480 · Cited by 123
Liu, X., Bai, X.-F., Wen, J., Gao, J.-X., Liu, J., Lu, P., Wang, Y., Zheng, P., & Liu, Y. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.194.9.1339 · Cited by 119 · cited 3×
“Furthermore, it has been shown that optimal induction of antitumor immunity through B7-H2 costimulation requires cotransfection of B7-1 or expression of B7-1 on APCs in the tumor microenvironment, demonstrating that B7-H2 acts to costimulate CTLs primarily in the postpriming phases of CTL activation.(36) Finally, data…”
BackgroundStanciu, L. A., Bellettato, C. M., Laza‐Stanca, V., Coyle, A. J., Papi, A. A., & Johnston, S. L. (2006) · The Journal of Infectious Diseases · doi:10.1086/499275 · Cited by 117
Lee, I. T., Wang, L., Wells, A. D., Ye, Q., Han, R., Dorf, M. E., Kuziel, W. A., Rollins, B. J., Chen, L., & Hancock, W. W. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.171.12.6929 · Cited by 116
Self-citationPredominant expression of B7-H1 and its immunoregulatory roles in oral squamous cell carcinoma
Tsushima, F., Tanaka, K., Otsuki, N., Youngnak‐Piboonratanakit, P., Iwai, H., Omura, K., & Azuma, M. (2005) · Oral Oncology · doi:10.1016/j.oraloncology.2005.07.013 · Cited by 112
LICOS, a primordial costimulatory ligand?
Brodie, D. W., Collins, A. V., Iaboni, A., Fennelly, J. A., Sparks, L. M., Xu, X.-N., van der Merwe, P. A., & Davis, S. J. (2000) · Current Biology · doi:10.1016/s0960-9822(00)00383-3 · Cited by 111
B7‐H3 promotes acute and chronic allograft rejection
Wang, L., Fraser, C. C., Kikly, K., Wells, A. D., Han, R., Coyle, A. J., Chen, L., & Hancock, W. W. (2005) · European Journal of Immunology · doi:10.1002/eji.200425518 · Cited by 102
Self-citationThe immune regulatory protein B7-H3 promotes osteoblast differentiation and bone mineralization
Suh, W.-K., Wang, S. X., Jheon, A. H., Moreno, L., Yoshinaga, S. K., Ganss, B., Sodek, J., Grynpas, M. D., & Mak, T. W. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0405259101 · Cited by 93 · cited 1×
“Moreover, this molecule may potentially play a diverse role in the regulation of growth and differentiation of nonhematopoietic tissues.(41,45,46) Unfortunately, all studies to date have been hindered by the as-yet-unidentified receptor(s), expressed primarily on activated T and NK cells.”
BackgroundHe, Y., Wang, X., Zhang, G., Chen, H., Zhang, H., & Feng, Z. (2005) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-004-0654-1 · Cited by 88
Geng, H., Zhang, G., Han, X., Yuan, Y., Li, D., Zhang, H., Qiu, H., He, Y., & Feng, Z. (2006) · International Journal of Cancer · doi:10.1002/ijc.21795 · Cited by 87
Ogasawara, K., Yoshinaga, S. K., & Lanier, L. L. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.169.7.3676 · Cited by 87
The balance of immune responses: costimulation verse coinhibition
Subudhi, S. K., Alegre, M., & Fu, Y. (2005) · Journal of Molecular Medicine · doi:10.1007/s00109-004-0617-1 · Cited by 82 · cited 1×
“As follows the route of identification, B7-H1 tends to promote tumor growth and immune suppression, whereas B7-DC seems to favor costimulation of antitumor immunity, although controversy persists as to the stimulatory versus inhibitory nature of both molecules.(17,18) Both molecules bind the inhibitory receptor PD-1 (…”
BackgroundCostimulatory wars: the tumor menace
Hurwitz, A. A., Kwon, E. D., & van Elsas, A. (2000) · Current Opinion in Immunology · doi:10.1016/s0952-7915(00)00147-3 · Cited by 80 · cited 2×
“Along these lines, much can be learned from previous immunotherapy studies with the original B7s.10,11 Certainly, the new B7s will play a vital and exciting role in building on the early successes of adoptive and molecular immunotherapy.12,13”
ResultCurrent developments of immunotherapy in the clinic
Antonia, S. J., Mulé, J. J., & Weber, J. S. (2004) · Current Opinion in Immunology · doi:10.1016/j.coi.2004.01.012 · Cited by 78 · cited 1×
“Lately, a variety of cancer vaccines, adoptive cell transfer therapies (ACT) combined with preconditioning regimens, and molecular immunotherapies have achieved variable success in the clinic.(13,104,105) Please refer to the review by Gattinoni et al(13) for an update on adoptive immunotherapy for cancer.”
BackgroundThe evolving crosstalk between co-stimulatory and co-inhibitory receptors: HVEM–BTLA
Croft, M. (2005) · Trends in Immunology · doi:10.1016/j.it.2005.03.010 · Cited by 77 · cited 1×
“Although it may be likely that unidentified receptors may belong to the CD28 family of molecules, we only need to look at BTLA:HVEM interactions to realize that anything is possible.(117) The search continues to be difficult due primarily to low receptor:ligand affinities.”
BackgroundT lymphocyte co-signaling pathways of the B7-CD28 family.
Wang, S., & Chen, L. (2004) · PubMed · Cited by 74
Self-citationAn Orthotopic Colon Cancer Model for Studying the B7-H3 Antitumor Effect In Vivo
Lupu, C., Eisenbach, C., Kuefner, M. A., Schmidt, J., Lupu, A., Stremmel, W., & Encke, J. (2006) · Journal of Gastrointestinal Surgery · doi:10.1007/bf03239969 · Cited by 68
Co-inhibitory role of T-cell-associated B7-H1 and B7-DC in the T-cell immune response
Seo, S., Seo, H.-M., Jeong, H.-Y., Choi, I.-W., Park, Y.-M., Yagita∥, H., Chen, L., & Choi, I.-H. (2005) · Immunology Letters · doi:10.1016/j.imlet.2005.09.007 · Cited by 62
Self-citationMasao, I. (2005) · Frontiers in bioscience · doi:10.2741/1742 · Cited by 57 · cited 1×
“53 Both molecules are significantly expressed on the surface of many human cancers, whereas protein expression is low or undetectable in normal tissues.(53) Although there tends to be overlapping expression patterns for B7-H1 and B7-H4 on many tumor types, some cancers such as melanoma exhibit a differential expressio…”
BackgroundCytosine arabinoside induces costimulatory molecule expression in acute myeloid leukemia cells
Vereecque, R., Saudemont, A., & Quesnel, B. (2004) · Leukemia · doi:10.1038/sj.leu.2403391 · Cited by 55
The role of leukemia-derived B7-H1 (PD-L1) in tumor–T-cell interactions in humans
Salih, H. R., Wintterle, S., Krusch, M., Kroner, A., Huang, Y.-H., Chen, L., & Wiendl, H. (2006) · Experimental Hematology · doi:10.1016/j.exphem.2006.03.006 · Cited by 53 · cited 1×
“B7-H1 is found to be highly expressed in carcinomas of colon, breast, ovarian, lung and melanoma cancer,(54,55) oral squamous cell carcinoma,(56) head and neck cancers,(57) glioma,(58) nonsmall cell lung carcinoma,(59) renal cell carcinoma,(60) gastric carcinoma,61 and esophageal cancer,(62) and leukemias.(63) B7-H4 i…”
BackgroundSelf-citationTRICOM Vector Based Cancer Vaccines
Garnett‐Benson, C., Greiner, J. W., Tsang, K.-Y., Kudo‐Saito, C., Grosenbach, D. W., Chakraborty, M., Gulley, J. L., Arlen, P. M., Schlom, J., & Hodge, J. W. (2005) · Current Pharmaceutical Design · doi:10.2174/138161206775201929 · Cited by 53 · cited 1×
“Lately, a variety of cancer vaccines, adoptive cell transfer therapies (ACT) combined with preconditioning regimens, and molecular immunotherapies have achieved variable success in the clinic.(13,104,105) Please refer to the review by Gattinoni et al(13) for an update on adoptive immunotherapy for cancer.”
BackgroundGrabmeier‐Pfistershammer, K., Klauser, C., Pickl, W. F., Stöckl, J., Leitner, J. M., Zlabinger, G. J., Majdic, O., & Steinberger, P. (2006) · European Journal of Immunology · doi:10.1002/eji.200535344 · Cited by 50 · cited 1×
“These data are clearly in agreement with previous studies showing a costimulatory role for B7-DC in a PD-1–independent manner,(21,95) although lines of evidence certainly confirm a role for B7-DC–mediated inhibition of T-cell responses in a PD1–dependent fashion.(96) Sufficient in vitro data now also exist to verify t…”
ResultCloning and Identification of Two Novel Splice Variants of Human PD-L2
He, X., Liu, Y., Xu, L., & Zeng, Y.-Y. (2004) · Acta Biochimica et Biophysica Sinica · doi:10.1093/abbs/36.4.284 · Cited by 48 · cited 2×
“Evidence of 3 B7-DC splice variants and the likelihood of reverse signaling through the intracellular domain make studies of this receptorligand pathway exceedingly complex.(20,21) Indeed, studies in autoimmune models show widely varying outcomes in B7-H1 versus B7-DC blockade, neither of which correlate well with PD-…”
BackgroundResultGrimbacher, B., Warnatz, K., & Peter, H. (2003) · Current Opinion in Allergy and Clinical Immunology · doi:10.1097/00130832-200312000-00001 · Cited by 47
Expression of the B7‐related molecule ICOSL by human glioma cells in vitro and in vivo
Schreiner, B., Wischhusen, J., Mitsdoerffer, M., Schneider, D., Bornemann, A., Melms, A., Tolosa, E., Weller, M., & Wiendl, H. (2003) · Glia · doi:10.1002/glia.10291 · Cited by 42
Parney, I. F., Chang, L.-J., Farr-Jones, M. A., Hao, C., Smylie, M., & Petruk, K. C. (2006) · Journal of Neuro-Oncology · doi:10.1007/s11060-005-9058-0 · Cited by 42 · cited 1×
“4).(107,108) Even though potent antiimmune responses can now be generated both in vitro (for ACT) and in vivo, a bevy of inhibitory mechanisms naturally bring immune responses under control before a cancer can be completely eradicated.”
BackgroundMonoclonal and bispecific antibodies as novel therapeutics
Booy, E. P., Johar, D., Maddika, S., Pirzada, H., Sahib, M. M., Gehrke, I., Loewen, S., Louis, S. F., Kadkhoda, K., Mowat, M. R. A., et al. (2006) · Archivum Immunologiae et Therapiae Experimentalis · doi:10.1007/s00005-006-0011-5 · Cited by 40 · cited 1×
“Currently, a large number of monoclonal antibodies targeting costimulatory molecules are being developed which may prove impressive when used alone or in combination with other immunotherapy protocols.(106) Unfortunately, little opportunity exists at this time for agonistic mAbs against B7 family molecules, with the p…”
BackgroundImmunomodulation using the recombinant monoclonal human B7-DC cross-linking antibody rHIgM12
Keulen, V. P. V., Ciric, B., Radhakrishnan, S., Heckman, K. L., Mitsunaga, Y., Iijima, K., Kita, H., Rodriguez, M., & Pease, L. R. (2005) · Clinical & Experimental Immunology · doi:10.1111/j.1365-2249.2005.02992.x · Cited by 39 · cited 1×
“Unfortunately, little opportunity exists at this time for agonistic mAbs against B7 family molecules, with the possible exception of the rHIgM12 mAb against B7-DC which activates DCs through a reverse signaling mechanism.(99) Yet specific methods for up-regulating the costimulatory effect of B7-DC, B7-H2, and B7-H3 in…”
BackgroundSaatian, B., Yu, X.-Y., Lane, A. P., Doyle, T., Casolaro, V., & Spannhake, E. W. (2004) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00132.2003 · Cited by 35 · cited 3×
“Moreover, this molecule may potentially play a diverse role in the regulation of growth and differentiation of nonhematopoietic tissues.(41,45,46) Unfortunately, all studies to date have been hindered by the as-yet-unidentified receptor(s), expressed primarily on activated T and NK cells.”
BackgroundTherapeutic opportunities in the B7/CD28 family of ligands and receptors
Carreno, B. M., Carter, L., & Collins, M. (2005) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2005.02.003 · Cited by 32 · cited 2×
“Along these lines, much can be learned from previous immunotherapy studies with the original B7s.10,11 Certainly, the new B7s will play a vital and exciting role in building on the early successes of adoptive and molecular immunotherapy.12,13”
ResultICOS: A New Costimulatory Ligand/Receptor Pair and Its Role in T-Cell Activion
Richter, G. H. S., & Burdach, S. E. G. (2004) · Oncology Research and Treatment · doi:10.1159/000075612 · Cited by 27 · cited 2×
“As B7-H2 plays a primary role in B-cell function and costimulating TH2 responses, it is reasonable that B7-H2 expression of B-cell malignancies might mistakenly enable transformed cells to suppress any potential mounting immune responses.34 In contrast, B7-H2 transfection on solid tumors induces strong CD8+ CTL-mediat…”
BackgroundLane, A. P., Saatian, B., Yu, X., & Spannhake, E. W. (2004) · The Laryngoscope · doi:10.1097/00005537-200410000-00028 · Cited by 23
Sinomenine inhibits B7-H1 and B7-DC expression on human renal tubular epithelial cells
Chen, Y., Li, J., Zhang, J., Zhao, T., Zou, L., Tang, Y., Zhang, X., & Wu, Y. (2005) · International Immunopharmacology · doi:10.1016/j.intimp.2005.03.015 · Cited by 23
B7molecule mRNA expression in colorectal carcinoma
Xiao, J., Bai, P., Lai, B.-C., Li, L., Zhu, J., & Wang, Y.-L. (2005) · World Journal of Gastroenterology · doi:10.3748/wjg.v11.i36.5655 · Cited by 11
Xiao, D., Wen, J.-F., Li, J.-H., Hu, Z.-L., Zheng, H., & Fu, C.-Y. (2005) · World Journal of Gastroenterology · doi:10.3748/wjg.v11.i3.348 · Cited by 8
Cited by
Taube, J. M., Klein, A., Brahmer, J. R., Xu, H., Pan, X., Kim, J. H., Chen, L., Pardoll, D. M., Topalian, S. L., & Anders, R. A. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-3271 · Cited by 2,324
Self-citationTaube, J. M., Anders, R. A., Young, G. D., Xu, H., Sharma, R., McMiller, T. L., Chen, S., Klein, A. P., Pardoll, D. M., Topalian, S. L., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003689 · Cited by 2,157
Self-citationSubsets of Myeloid-Derived Suppressor Cells in Tumor-Bearing Mice
Youn, J.-I., Nagaraj, S., Collazo, M., & Gabrilovich, D. I. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.8.5791 · Cited by 1,645
VISTA is an immune checkpoint molecule for human T cells
Lines, J. L., Pantazi, E., Mak, J., Sempere, L. F., Wang, L., O'Connell, S., Ceeraz, S., Suriawinata, A. A., Yan, S., Ernstoff, M. S., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-1504 · Cited by 510
Madore, J., Vilain, R. E., Menzies, A. M., Kakavand, H., Wilmott, J. S., Hyman, J., Yearley, J. H., Kefford, R. F., Thompson, J. F., Long, G. V., et al. (2015) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12340 · Cited by 398
Metadata
- Authors
- Flies, D. B., & Chen, L.
- Venue
- Journal of Immunotherapy
- Published
- 2007-04
- Volume
- 30
- Issue
- 3
- Pages
- 251-260
- ISSN
- 1524-9557 (ISSN-L)
- OpenAlex
- W2086734209
- Cited by
- 189
- References
- 118
- FWCI
- 5.58
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.